Ipsen to buy Kartos Therapeutics for USD 450 million upfront, with up to USD 1.3 billion in milestones

  • Ipsen agreed to buy Kartos Therapeutics for USD 450 million upfront, adding late-stage myelofibrosis drug candidate navtemadlin.
  • Deal includes up to USD 1.3 billion in additional milestones tied to regulatory approval and sales performance.
  • Navtemadlin is an oral MDM2 inhibitor in the Phase III POIESIS trial as an add-on to ruxolitinib; top-line data expected in 2027.
  • Closing is targeted by end-Q3 2026; Ipsen expects the deal to be accretive to core operating income from 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290100OMX_____CNEWS_EN_GNW1001210007_en) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.